Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
This study will examine the inhibition of ErbB1 and ErbB2 phosphorylation and downstream mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer patients for three dosing schedules of lapatinib.
Epistemonikos ID: 6295a7cbb4721b3fb4f1e6bd5774a969418a1665
First added on: May 04, 2024